{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ras+%28Kras+or+Nras%29+Gene+Mutation",
    "query": {
      "condition": "Ras (Kras or Nras) Gene Mutation"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-21T23:28:41.820Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06270082",
      "title": "Study of IK-595 in RAS- or RAF-altered Advanced Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Colorectal Cancer",
        "Pancreatic Cancer",
        "Malignant Melanoma",
        "Ras (Kras or Nras) Gene Mutation",
        "BRAF Gene Mutation",
        "CRAF Gene Mutation",
        "Non-Small Cell Lung Carcinoma",
        "Thyroid Carcinoma",
        "Gliomas, Malignant"
      ],
      "interventions": [
        {
          "name": "IK-595",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ikena Oncology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2023-12-18",
      "completion_date": "2025-09-08",
      "has_results": false,
      "last_update_posted_date": "2025-09-19",
      "last_synced_at": "2026-05-21T23:28:41.820Z",
      "location_count": 15,
      "location_summary": "Duarte, California • Orange, California • Denver, Colorado + 12 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06270082"
    },
    {
      "nct_id": "NCT07252479",
      "title": "Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors (Phase 1)",
        "RAS Mutation"
      ],
      "interventions": [
        {
          "name": "AN9025 oral capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Adlai Nortye Biopharma Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 91,
      "start_date": "2026-01-28",
      "completion_date": "2028-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-11",
      "last_synced_at": "2026-05-21T23:28:41.820Z",
      "location_count": 2,
      "location_summary": "Orlando, Florida • Houston, Texas",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07252479"
    },
    {
      "nct_id": "NCT06881784",
      "title": "Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "NSCLC (Non-small Cell Lung Cancer)",
        "Non-Small Cell Lung Cancer",
        "NSCLC",
        "NSCLC (Non-small Cell Lung Carcinoma)",
        "NSCLC (Advanced Non-small Cell Lung Cancer)"
      ],
      "interventions": [
        {
          "name": "daraxonrasib",
          "type": "DRUG"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revolution Medicines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 420,
      "start_date": "2025-05-06",
      "completion_date": "2030-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-05-21T23:28:41.820Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Long Beach, California • New Haven, Connecticut + 30 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06881784"
    },
    {
      "nct_id": "NCT06326411",
      "title": "A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Oncology",
        "MEK Mutation",
        "RAF Gene Mutation",
        "Ras (KRAS or NRAS) Gene Mutation",
        "Melanoma",
        "NSCLC",
        "Glioma",
        "Solid Tumor, Adult",
        "MAPK Pathway Gene Mutation"
      ],
      "interventions": [
        {
          "name": "NST-628",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nested Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 230,
      "start_date": "2024-04-09",
      "completion_date": "2029-11",
      "has_results": false,
      "last_update_posted_date": "2026-04-20",
      "last_synced_at": "2026-05-21T23:28:41.820Z",
      "location_count": 17,
      "location_summary": "San Francisco, California • Westwood, Los Angeles, California • Denver, Colorado + 11 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Westwood, Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06326411"
    },
    {
      "nct_id": "NCT05593328",
      "title": "Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Onvansertib",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cardiff Oncology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2023-03-17",
      "completion_date": "2024-12-09",
      "has_results": false,
      "last_update_posted_date": "2025-01-10",
      "last_synced_at": "2026-05-21T23:28:41.820Z",
      "location_count": 27,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 24 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05593328"
    },
    {
      "nct_id": "NCT07252232",
      "title": "Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "PDAC",
        "PDAC - Pancreatic Ductal Adenocarcinoma",
        "Resectable Pancreatic Ductal Adenocarcinoma (PDAC)",
        "Resected Pancreatic Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "daraxonrasib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revolution Medicines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 500,
      "start_date": "2025-12-15",
      "completion_date": "2030-07-10",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-05-21T23:28:41.820Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • San Francisco, California • Hartford, Connecticut + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Lawrence",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07252232"
    },
    {
      "nct_id": "NCT07397338",
      "title": "Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Metastatic Solid Tumors",
        "Non-small Cell Lung Cancer (NSCLC)",
        "NSCLC",
        "Colorectal Cancer (CRC)",
        "CRC"
      ],
      "interventions": [
        {
          "name": "Daraxonrasib",
          "type": "DRUG"
        },
        {
          "name": "Elironrasib",
          "type": "DRUG"
        },
        {
          "name": "Zoldonrasib",
          "type": "DRUG"
        },
        {
          "name": "Ivonescimab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)",
          "type": "DRUG"
        },
        {
          "name": "cetuximab (Cohort C2 Only)",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only)",
          "type": "DRUG"
        },
        {
          "name": "Daraxonrasib (Cohort B1 only)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revolution Medicines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 370,
      "start_date": "2026-01-30",
      "completion_date": "2029-05",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-05-21T23:28:41.820Z",
      "location_count": 5,
      "location_summary": "Norwich, Connecticut • Nashville, Tennessee • Irving, Texas + 2 more",
      "locations": [
        {
          "city": "Norwich",
          "state": "Connecticut"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Irving",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07397338"
    },
    {
      "nct_id": "NCT07491445",
      "title": "Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Pancreatic Cancer Metastatic",
        "PDAC",
        "PDAC - Pancreatic Ductal Adenocarcinoma",
        "Pancreatic Ductal Adenocarcinoma (PDAC)",
        "Pancreatic Adenocarcinoma Metastatic",
        "Pancreatic Adenocarcinoma",
        "Pancreatic Adenosquamous Carcinoma"
      ],
      "interventions": [
        {
          "name": "daraxonrasib",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "nab-paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revolution Medicines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 900,
      "start_date": "2026-03-09",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2026-05-14",
      "last_synced_at": "2026-05-21T23:28:41.820Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Henderson, Nevada • Maumee, Ohio",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Henderson",
          "state": "Nevada"
        },
        {
          "city": "Maumee",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07491445"
    }
  ]
}